摘要
目的探究特发性血小板减少性紫癜采用重组人血小板生成素联合环孢素A治疗的临床疗效。方法选取48例特发性血小板减少性紫癜患者,随机分为对照组和观察组,各组均24例,分别采用环孢素A与重组人血小板生成素联合环孢素A治疗。结果观察组患者治疗总有效率高于对照组(P<0.05),患者血小板计数高于对照组(P<0.05)。结论特发性血小板减少性紫癜采用重组人血小板生成素联合环孢素A治疗,治疗效果良好。
Objective To study the clinical efficacy of recombinant human thrombopoietin and cyclosporine in idiopathic thrombocytopenic purpura. MethodsSelected 48 cases of idiopathic thrombocytopenic purpura,randomly divided into control group and observation group,24 cases in each group,using cyclosporine A and recombinant human thrombopoietin combined with cyclosporine A treatment.Results The total effective rate of the observation group was significantly higher than that of the control group（P〈 0.05）,platelet count was higher in patients than in control group（P〈 0.05）.Conclusion Idiopathic thrombocytopenic purpura by recombinant human thrombopoietin combined with cyclosporine A treatment,treatment effect is good.
出处
《中国卫生标准管理》
2015年第20期107-108,共2页
China Health Standard Management
